|
Alopecia
|
|
0.710 |
GeneticVariation
|
GWASCAT |
Genetic prediction of male pattern baldness.
|
28196072 |
2017 |
|
Alopecia
|
|
0.710 |
GeneticVariation
|
BEFREE |
Our study provides evidence that the SRD5A2 A49T A variant is associated with an increased risk of prostate cancer, lower levels of circulating 3alpha-diolG and decreased risk of baldness.
|
17136762 |
2007 |
|
Alopecia, Androgenetic, 3
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Detection and interpretation of shared genetic influences on 42 human traits.
|
27182965 |
2016 |
|
Other alopecia
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Detection and interpretation of shared genetic influences on 42 human traits.
|
27182965 |
2016 |
|
Androgenetic Alopecia
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Detection and interpretation of shared genetic influences on 42 human traits.
|
27182965 |
2016 |
|
Alopecia, Male Pattern
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Detection and interpretation of shared genetic influences on 42 human traits.
|
27182965 |
2016 |
|
Alopecia, Androgenetic, 1
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Detection and interpretation of shared genetic influences on 42 human traits.
|
27182965 |
2016 |
|
Alopecia, Androgenetic, 2
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Detection and interpretation of shared genetic influences on 42 human traits.
|
27182965 |
2016 |
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
The overall results demonstrated that SRD5A2 rs9282858 polymorphism was remarkably associated with increased susceptibility of PCa (TT vs. AA: OR = 4.08, 95% CI = 1.94-8.58; TT + AT vs. AA: OR = 1.28, 95% CI = 1.11-1.47; TT vs. AA + AT: OR = 4.44, 95% CI = 2.12-9.27; allele T vs. allele A: OR = 1.34, 95% CI = 1.17-1.54).
|
28489754 |
2017 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The overall results demonstrated that SRD5A2 rs9282858 polymorphism was remarkably associated with increased susceptibility of PCa (TT vs. AA: OR = 4.08, 95% CI = 1.94-8.58; TT + AT vs. AA: OR = 1.28, 95% CI = 1.11-1.47; TT vs. AA + AT: OR = 4.44, 95% CI = 2.12-9.27; allele T vs. allele A: OR = 1.34, 95% CI = 1.17-1.54).
|
28489754 |
2017 |
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although there was no overall association between V89L and prostate cancer risk, A49T might play a role in the etiology of prostate cancer among Caucasians.
|
23277398 |
2013 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although there was no overall association between V89L and prostate cancer risk, A49T might play a role in the etiology of prostate cancer among Caucasians.
|
23277398 |
2013 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk.
|
21177315 |
2011 |
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk.
|
21177315 |
2011 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The authors found that prostate cancer was not associated with V89L (L allele vs. V allele: odds ratio = 0.99, 95% confidence interval: 0.94, 1.05) and was probably not associated with A49T (T allele vs. A allele: odds ratio = 1.10, 95% confidence interval: 0.86, 1.40).
|
19914946 |
2010 |
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
The authors found that prostate cancer was not associated with V89L (L allele vs. V allele: odds ratio = 0.99, 95% confidence interval: 0.94, 1.05) and was probably not associated with A49T (T allele vs. A allele: odds ratio = 1.10, 95% confidence interval: 0.86, 1.40).
|
19914946 |
2010 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study tested the interactions of VDR (CDX2, FokI) and SRD5A2 (V89L, A49T) polymorphisms, and their associations with prostate cancer.
|
18483391 |
2008 |
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study tested the interactions of VDR (CDX2, FokI) and SRD5A2 (V89L, A49T) polymorphisms, and their associations with prostate cancer.
|
18483391 |
2008 |
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
After evaluating more than 6000 cases and 6000 controls, there is little evidence of a role for the SRD5A2 A49T variant in prostate cancer</span> risk.
|
18469342 |
2008 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
After evaluating more than 6000 cases and 6000 controls, there is little evidence of a role for the SRD5A2 A49T variant in prostate cancer</span> risk.
|
18469342 |
2008 |
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
Carriers of the rarer A49T A allele were at a 60% higher risk of prostate cancer (OR = 1.60; 95% CI 1.09-2.36; p = 0.02) and 50% lower risk of vertex and frontal balding (p = 0.03) compared with men homozygous for the more common G allele.
|
17136762 |
2007 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Carriers of the rarer A49T A allele were at a 60% higher risk of prostate cancer (OR = 1.60; 95% CI 1.09-2.36; p = 0.02) and 50% lower risk of vertex and frontal balding (p = 0.03) compared with men homozygous for the more common G allele.
|
17136762 |
2007 |
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prostate cancer and BPH were not associated with the alanine-49 to threonine single nucleotide polymorphism and the (TA)n repeat.
|
16018939 |
2005 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prostate cancer and BPH were not associated with the alanine-49 to threonine single nucleotide polymorphism and the (TA)n repeat.
|
16018939 |
2005 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |